Characteristics of the study group by therapy (percentage)
| . | Regimen . | P . | |||||
|---|---|---|---|---|---|---|---|
| IA . | DA . | FA . | FAI . | TA . | CA . | ||
| Overall number | 438 | 149 | 278 | 279 | 330 | 60 | |
| Age, 60 y or older (%) | 36 | 44 | 44 | 61 | 52 | 58 | <.001 |
| Karyotype (%) | |||||||
| Favorable | 8 | 5 | 22 | 1 | 6 | 0 | <.001 |
| Diploid | 43 | 26 | 25 | 26 | 49 | 50 | <.001 |
| 5 or 7 abnormalities | 17 | 33 | 26 | 35 | 22 | 25 | <.001 |
| Others | 27 | 30 | 22 | 32 | 20 | 23 | .008 |
| Insufficient metaphases | 5 | 6 | 5 | 6 | 2 | 2 | .2 |
| . | Regimen . | P . | |||||
|---|---|---|---|---|---|---|---|
| IA . | DA . | FA . | FAI . | TA . | CA . | ||
| Overall number | 438 | 149 | 278 | 279 | 330 | 60 | |
| Age, 60 y or older (%) | 36 | 44 | 44 | 61 | 52 | 58 | <.001 |
| Karyotype (%) | |||||||
| Favorable | 8 | 5 | 22 | 1 | 6 | 0 | <.001 |
| Diploid | 43 | 26 | 25 | 26 | 49 | 50 | <.001 |
| 5 or 7 abnormalities | 17 | 33 | 26 | 35 | 22 | 25 | <.001 |
| Others | 27 | 30 | 22 | 32 | 20 | 23 | .008 |
| Insufficient metaphases | 5 | 6 | 5 | 6 | 2 | 2 | .2 |